What happened

In June 2025 the FDA conducted a raid on Amino Asylum. The company went permanently offline within hours: payment processing was cut, the website returned a server error, and thousands of pending orders were never shipped. There was no customer notice.

The federal charges that triggered the raid concerned products labeled as SARMs that, on testing, contained testosterone — a controlled substance. A parallel pattern of inconsistent COA practices across the broader catalog raises questions about quality control on peptides as well, though no formal peptide-specific charges were brought.

Scale before the shutdown

Pre-raid traffic estimates put Amino Asylum at 400,000+ monthly website visitors, making it one of the top five most-searched peptide vendors in the United States. The community impact of the closure was substantial: researchers who had relied on Amino Asylum's pricing and catalog depth discovered, often for the first time, the importance of independent COAs and third-party testing.

What this audit page exists for

We keep this page live for three reasons:

1. Historical record. The methodology page commits to never quietly rewriting history. The Amino Asylum audit existed; it now reflects the vendor's terminal status.
2. Reader signal. Search traffic still arrives via "is amino asylum still operating" and similar queries. Better that those readers land on accurate shutdown information than on a thirty-source aggregator.
3. Editorial precedent. Vendor closures are now a recurring event in this market — Peptide Sciences (March 2026) and Paradigm Peptides (December 2025) followed the same pattern. We document them.

Where the catalog migrated

The displaced reader population has largely moved to: Limitless Biotech (formerly Limitless Life Nootropics) and Particle Peptides for the GLP-1 segment Amino Asylum dominated. Both have current preview profiles on this site; first-hand audits land when the audit cycle ships.